U.S. and Canadian researchers have shown that the generic drug N-acetylcysteine, which is sold over the counter for some uses, could potentially be repurposed to treat thrombotic thrombocytopenic purpura, a hematological disorder for which cumbersome plasma exchange therapy has been the standard of care for nearly two decades.